BEIJING—Clinical trials being conducted in Wuhan to test Gilead Sciences Inc.’s antiviral drug, a promising remedy for the new coronavirus, are going more slowly than hoped for as the drugmaker struggles to recruit qualified patients, underscoring the challenges in quickly developing drugs during outbreaks.
Gilead’s Coronavirus Drug Trial Slowed by Lack of Eligible Recruits
BEIJING—Clinical trials being conducted in Wuhan to test Gilead Sciences Inc.’s antiviral drug, a promising remedy for the new coronavirus, are going more slowly than hoped for as the drugmaker struggles to recruit qualified patients, underscoring the challenges in quickly developing drugs during outbreaks.
主要的阻碍来自于：
病人必须12 天之内发病， 30天内未接受过其他治疗？？？？